证券日报网讯 11月12日晚间，华恒生物发布公告称，选举郭恒华女士为公司第五届董事会董事长。 ...

Core Insights - The report maintains a neutral rating for the pharmaceutical and biotechnology industry, indicating that while there are pressures on performance, there are also opportunities in specific segments that are experiencing growth [5][30]. Market Performance Review - In the first ten months of 2025, the SW pharmaceutical and biotechnology index increased by 21.10%, outperforming the CSI 300 index by approximately 2.26 percentage points, ranking 12th among all Shenwan primary industries [14][19]. - Most sub-sectors within the industry recorded positive returns, with the medical research outsourcing and chemical preparation sectors leading with increases of 60.54% and 40.80%, respectively. Conversely, the blood products and vaccine sectors saw declines of 7.89% and 1.60% [15][19]. - As of October 31, 2025, the overall price-to-earnings (PE) ratio for the SW pharmaceutical and biotechnology industry was approximately 53.97 times, which is 4.06 times higher than the CSI 300 index, indicating an increase in industry valuation [19][20]. Policy Outlook for H1 2026 - The 11th batch of national drug centralized procurement is expected to be fully implemented in the first half of 2026, involving 55 varieties and 272 companies, with a selection rate of 57% [30][31]. - The procurement results show a high match between selected brands and clinical needs, with strong supply capabilities from mainstream companies [30]. Sub-sector Highlights Innovative Drugs - Continuous policy optimization supports the development of innovative drugs, with a comprehensive approach to enhance pricing management, insurance coverage, and investment [38]. - The industry is gradually moving away from homogeneous competition, with a significant increase in the proportion of First-in-Class new drug development, which rose by 23 percentage points to 35% since 2020 [38][39]. - Domestic innovative drugs are gaining international recognition, with outbound licensing transactions reaching $66 billion in the first half of 2025, reflecting a growing global presence [41][44]. Medical Devices - The aging population in China is projected to exceed 400 million by 2035, driving demand for medical services and supporting stable growth in the medical device market [50]. - The global medical device market is expected to grow at a compound annual growth rate (CAGR) of 5.7%, reaching $869.7 billion by 2030 [52]. - China's medical device market is rapidly expanding, with projected revenues of 187.5 billion yuan by 2025, indicating significant growth potential [53]. Aesthetic Medicine - The domestic aesthetic medicine market is expected to steadily increase, supported by various policies aimed at promoting healthy industry development and improving market concentration [39]. Synthetic Biology - The market size for synthetic biology is anticipated to approach $40 billion by 2027, driven by multiple factors including technological advancements and increased investment [39].

证券代码：688639 证券简称：华恒生物 公告编号：2025-052 安徽华恒生物科技股份有限公司 关于董事会完成换届选举及聘任高级管理人员、证券 事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 安徽华恒生物科技股份有限公司于 2025 年 11 月 12 日召开 2025 年第三次临 时股东会，选举产生了第五届董事会非职工董事，与公司于 2025 年 10 月 27 日 召开的 2025 年第二次职工代表大会选举出的职工代表董事共同组成公司第五届 董事会。同日，公司召开第五届董事会第一次会议，审议通过了选举公司董事长、 各专门委员会委员、聘任高级管理人员和证券事务代表等相关议案。现将具体情 况公告如下： 董事会战略与 ESG 委员会组成人数为三人，分别为：郭恒华、张学礼、WANG FUCAI(王富才)，其中郭恒华为召集人。 董事会审计委员会组成人数为三人，分别为：陈继忠、吴林、郭恒平，其中 陈继忠为召集人。 董事会提名委员会组成人数为三人，分别为：吴林、WANG FUCAI(王富才)、 郭恒华，其中吴林 ...

1、《公司章程》； 2、公司 2025 年 10 月 27 日第四届董事会第二十四次会议决议和会议记录； 3、公司于 2025 年 10 月 28 日刊载于上海证券交易所网站的本次会议通知； 安徽天禾律师事务所 关于安徽华恒生物科技股份有限公司 2025 年第三次临时股东会之法律意见书 天律意 2025 第 02953 号 致：安徽华恒生物科技股份有限公司 根据《中华人民共和国公司法》(下称《公司法》)、《中华人民共和国证券 法》（下称《证券法》）的规定，以及贵公司（下称"公司"）与安徽天禾律师 事务所（下称"本所"）签订的《法律顾问合同》，本所律师出席公司 2025 年 第三次临时股东会，并对本次股东会相关事项进行了见证，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则（试行）》等规定，严格履行 了法定职责，遵循了勤勉尽责和诚实信用的原则，对本次股东会所涉及的相关事 项进行了必要的核查和验证，核查了本所认为出具本法律意见书所需的相关文件 和资料。为出具本法律意见，本所律师审查了公司提供的以下文件： 4、公司于 2025 年 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-051 安徽华恒生物科技股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 12 日 （二） 股东会召开的地点：合肥市高新区长安路 197 号公司 A1 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 38 | | --- | --- | | 普通股股东人数 | 38 | | 2、出席会议的股东所持有的表决权数量 | 92,555,264 | | 普通股股东所持有表决权数量 | 92,555,264 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 37.08 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 37.08 | 1、 公司在任董事 ...

Group 1 - The chemical raw materials sector experienced a significant upward movement on November 11, with Haike Xinyuan rising over 12% [2] - Sanfu Co., Ltd. reached its daily limit up, indicating strong investor interest [2] - Other stocks such as Huaheng Biological, Jinjing Technology, Hualitai, Heyuan Gas, and Kaisheng New Materials also saw gains, reflecting a broader positive trend in the sector [2]

Core Viewpoint - The Ministry of Industry and Information Technology (MIIT) has announced the list of selected units for the high-performance bioreactor innovation task, aiming to enhance the supply capacity of key equipment for biological manufacturing [2][3]. Summary by Relevant Sections Task Objectives - The initiative focuses on three categories: reactor systems, key components and consumables, and industrial operating systems, with a total of nine tasks aimed at selecting and nurturing units with strong innovation capabilities and mastery of core technologies [2]. Selected Units - Notable units included in the list are: - Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences - Guangzhou Aibaitai Biotechnology - Shanghai Dongfulong - Jiangsu Weiji Wisdom - Shanghai Shunyu Hengping - Shanghai Ailite [5][6]. Task Directions - The tasks cover various directions such as: 1. Microbial parallel bioreactors 2. Cell parallel bioreactors 3. Large cell bioreactors 4. Core physicochemical parameter in-situ monitoring 5. Biological reactor intelligent industrial operating systems [5][6]. Innovation Goals - The goal is to break through several landmark technologies, cultivate typical application scenarios, and accelerate the landing and application of new technologies and products, thereby enhancing the integrated development capability of high-performance bioreactors [2].

Core Viewpoint - The biopharmaceutical sector on the STAR Market has shown mixed performance, with the STAR Biopharmaceutical Index declining by 0.60% as of November 6, 2025, while individual stocks exhibited varied movements, indicating a potential for structural recovery in the sector [1][4]. Group 1: Market Performance - The STAR Biopharmaceutical Index decreased by 0.60% as of November 6, 2025, with stocks like Huaheng Biological leading gains at 2.86%, while Yifang Biological experienced the largest decline [1]. - The Jiashi STAR Biopharmaceutical ETF recorded a turnover of 6.67% and a transaction volume of 21.39 million yuan, reaching a new high of 322 million yuan in scale, ranking first among comparable funds [3]. - The Jiashi STAR Biopharmaceutical ETF has seen a net inflow of 56.85 million yuan over the past four days, with a peak single-day net inflow of 16.85 million yuan [3]. Group 2: Fund Performance - As of November 5, 2025, the Jiashi STAR Biopharmaceutical ETF has achieved a one-year net value increase of 26.53%, with the highest monthly return since inception being 23.29% and the longest consecutive monthly gain lasting seven months [3]. - The average monthly return during the rising months of the Jiashi STAR Biopharmaceutical ETF is 7.85% [3]. Group 3: Industry Outlook - Recent adjustments in the pharmaceutical sector are attributed to a recovery in capital market financing and an increase in the scale of innovative drug exports, leading to a rebound in domestic innovative drug research and development [3]. - The outlook for the innovative drug sector remains focused on business development (BD) expectations, with BD activities typically accounting for about 40% of annual transactions in the fourth quarter [3]. - According to data, the top ten weighted stocks in the STAR Biopharmaceutical Index account for 49.74% of the index, indicating a concentration of investment in key players [4][6].

安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688639 证券简称：华恒生物 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会 会议资料 中国合肥 二〇二五年十一月 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 2025 年第三次临时股东会会议资料 目 录 | 2025 年第三次临时股东会会议须知 1 | | --- | | 2025 年第三次临时股东会会议议程 3 | | 议案一：关于选举公司第五届董事会非独立董事的议案 4 | | 议案二：关于选举公司第五届董事会独立董事的议案 5 | 安徽华恒生物科技股份有限公司 2025 年第三次临时股东会会议资料 2025年第三次临时股东会会议须知 为了维护安徽华恒生物科技股份有限公司（以下简称"公司"）全体股东的 合法权益，确保股东会的正常秩序和议事效率，保证股东会的顺利进行，根据《中 华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下 简称"《证券法》"）《上市公司股东会规则》以及《安徽华恒生物科技股份有限公 司章程》（以下简称《公司章程》）等相关规定，特制定 2025 ...

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field that disrupts traditional production methods, presenting it as a new growth point for optimizing industrial structure and transforming economic models. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper outlines the development status and trends of biomanufacturing, analyzing the global landscape and key platform facilities [5]. - It compares the biomanufacturing sectors of China and the United States, identifying competitive advantages and areas for improvement [5]. - Future development trends in biomanufacturing are discussed, indicating a shift towards more integrated and sustainable practices [5]. Group 2: Policy Landscape - The report reviews major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025, providing insights into regulatory frameworks that could impact industry growth [5]. - It categorizes foreign and domestic policies, highlighting their implications for the biomanufacturing sector [5]. Group 3: Industry Map and Applications - A comprehensive map of the Chinese biomanufacturing industry is presented, detailing the key players and their roles within the ecosystem [5]. - The report identifies critical application areas for biomanufacturing, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5]. Group 4: Key Enterprises - The white paper lists the top 10 chain leader enterprises in China's biomanufacturing industry, providing a snapshot of the leading companies driving innovation and growth [6]. - It also details the strategic directions of 15 publicly listed companies in the synthetic biology space, summarizing their approaches to market opportunities [6]. Group 5: Investment and Challenges - The report discusses the investment landscape for synthetic biology in China, covering trends and funding activities from 2024 to mid-2025 [6]. - It addresses the challenges faced by the biomanufacturing industry in China, proposing targeted policy recommendations to overcome these obstacles [6].